A medical disorder known as Patent Foramen Ovale (PFO) occurs when a tissue flap in the wall between the left and right atrium remains open, enabling a little volume of blood to travel from the right side of the heart to the left side of the heart. PFO closure devices are implantable devices that are used to treat PFO using a catheter-based, minimally invasive technique. PFO has been linked to a variety of pathological conditions, including cryptogenic strokes, transient ischemic attacks, migraine with auras, decompression sickness, and severe refractory hypoxemia. The increased incidence rate of ischemic stroke and new product introductions are driving the PFO closure device market.
PFO Closure Device Market – Restrain
Patent foramen ovale (PFO) closure device market is expected to be hindered by product discontinuation or recall. For instance, in 2013, W. L. Gore & Associates, Inc, discontinued its product GORE HELEX Septal Occluder, as a result of sued for patent infringement. Moreover, in 2013, St. Jude Medical recalled Amplatzer PFO Occluder, assigned as Class I tagged product recall by FDA.
PFO Closure Device Market - Regional Analysis
Based on geography, the patent foramen ovale (PFO) closure device market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant market share attributed to high incidence of ischemic stroke. Furthermore, Asia Pacific is expected to fastest growing PFO closure device market due to increasing awareness among the population about PFO. For instance, PFO Funding Organization, Australia-based not for profit organization, works to increase public and physician awareness of the medical condition called patent foramen ovale (PFO) or ‘hole in the heart’ and its importance to cardiovascular and neurological health.
Read More: https://bit.ly/3Ez35Pe
